OptimizeRx Corporation has reported its financial results for the first quarter of 2025, revealing a notable performance. The company's revenue in Q1 2025 increased by 11% year-over-year, reaching $21.9 million, compared to $19.7 million in the same period of the previous year. Gross profit for the quarter also saw an increase of 9% year-over-year, amounting to $13.3 million. The company reported an improvement in adjusted EBITDA, which rose to $1.5 million in the first quarter of 2025, compared to a loss of $0.3 million in the same quarter of the prior year. OptimizeRx's cash, cash equivalents, and short-term investments totaled $16.6 million as of March 31, 2025, up from $13.4 million as of December 31, 2024. In light of these results, OptimizeRx has updated its full-year 2025 guidance, now forecasting revenue to be in the range of $101 million to $106 million, with adjusted EBITDA expected to fall between $13 million and $15 million. Stephen L. Silvestro, CEO of OptimizeRx, expressed optimism about the company's performance, citing a more than 20% increase in year-to-date contracted revenue compared to the same period last year, which positions the company well for a strong second half of the year.